Michael A. Mussallem - 03 Nov 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
03 Nov 2023
Net transactions value
-$893,120
Form type
4
Filing time
06 Nov 2023, 18:33:57 UTC
Previous filing
02 Oct 2023
Next filing
13 Dec 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $1,078,612 +29,350 +654% $36.75 33,836 03 Nov 2023 Direct F1
transaction EW Common Stock Sale $1,971,733 -29,350 -87% $67.18 4,486 03 Nov 2023 Direct F1, F2
transaction EW Common Stock Gift $0 -371,689 -100% $0.000000* 0 06 Nov 2023 401(k) F3
transaction EW Common Stock Gift $0 +371,689 +10% $0.000000 4,038,377 06 Nov 2023 By Living Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -29,350 -14% $0.000000 176,100 03 Nov 2023 Common Stock 29,350 $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $66.59 to $67.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 In connection with an in-kind transfer of shares from the Reporting Person's 401(k) account to his Living Trust, the remaining 0.7321 of one share was automatically sold by the 401(k) plan administrator at a price of $63.505269 per share, for a total of $46.50, to comply with the plan administrator's policy prohibiting the transfer of a fractional share.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.